Dr Charlotte Schutz

Clinical Research Officer

Affiliations

  1. Fellow, Institute of Infectious Disease and Molecular Medicine
  2. Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa)

Key Expertise

Management of HIV & HIV-associated infections

Main Research Focus

Charlotte has a keen interest in HIV-related opportunistic infections with a particular focus on severe HIV-associated tuberculosis, underlying pathophysiology and contributors to mortality. Through her work she aims to contribute to improved survival. She has completed an MBChB, DipHIVMan (SA), MPH (Clinical Research) and PhD in Medicine. She is part of the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa).

Most Significant Paper Authored in 2024

Elevated Plasma Matrix Metalloproteinases Are Associated With Mycobacterium Tuberculosis Bloodstream Infection and Mortality in Human Immunodeficiency Virus- Associated Tuberculosis

Walker NF, Schutz C, Ward A, Barr D, Opondo C, Shey M, Elkington PT, Wilkinson KA, Wilkinson RJ, Meintjes G (2024).  

The PURPOSE1 study is a significant contribution to HIV prevention, as it evaluated the efficacy of lenacapvir, a novel long-acting HIV prevention method, in adolescents and young women in sub-Saharan Africa (SSA). The study’s findings are critical for understanding how lenacapvir can effectively reduce HIV transmission in high-risk populations. The study demonstrated 100% in preventing HIV compared to oral PrEP. The research offers valuable insights into how long-acting methods can be a game-changer for HIV prevention. This has the potential to improve health outcomes for adolescents and young women in SSA, addressing gaps in current prevention approaches in resource-limited settings.